Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke

Summary

Early antiplatelet therapy is promising for further improvement of functional prognosis on the basis of intravenous thrombolytic therapy. The primary purpose of this multicenter, randomized, double-blind, placebo-parallel controlled trial is to evaluate the efficacy and safety of the early dual antiplatelet therapy (within 6 hours of onset ) of ticagrelor with aspirin combined with intravenous thrombolysis in improving good functional outcome (mRS score 0-1) at 90 days inpatients with ischemic stroke.

Timeline

Start

2024-04-03

Primary completion

2025-12-31

Completion

2026-01-05

Publications

• Wang A, Xia X, Tang Y, Zhang F, Han X, Li J, Zhang X, Wang J, Song Y, Che F, Bei Y, He Y, Jing W, Hao J, He J, Yang H, Chen S, Wu W, Li Y, Dai H, Yang C, Sun Z, Li L, Chen Y, Bath PM, Turc G, Wang Y; TAPIS Investigators. Ticagrelor with aspirin dual antiplatelet therapy combined with intravenous thrombolysis in patients with ischaemic stroke in China (TAPIS): a multicentre, double-blind, randomised controlled trial. Lancet. 2026 May 16;407(10542):1919-1928. doi: 10.1016/S0140-6736(26)00757-9. Epub 2026 May 8.
• Wang A, Xia X, Bath PM, Turc G, Li J, Zhang X, Wang Y. Rationale and design of Ticagrelor with Aspirin Dual Antiplatelet Therapy Combined with Intravenous Thrombolysis in Patients with Ischemic Stroke (TAPIS): a multicentre, randomised, double-blind, parallel group, placebo-controlled trial. Stroke Vasc Neurol. 2026 Jan 29:svn-2025-004721. doi: 10.1136/svn-2025-004721. Online ahead of print.

Drugs

Indications